Ketamine treatment for depression: a review
M Yavi, H Lee, ID Henter, LT Park, CA Zarate Jr - Discover mental health, 2022 - Springer
This manuscript reviews the clinical evidence regarding single-dose intravenous (IV)
administration of the novel glutamatergic modulator racemic (R, S)-ketamine (hereafter …
administration of the novel glutamatergic modulator racemic (R, S)-ketamine (hereafter …
Circadian depression: a mood disorder phenotype
JS Carpenter, JJ Crouse, EM Scott, SL Naismith… - Neuroscience & …, 2021 - Elsevier
Major mood syndromes are among the most common and disabling mental disorders.
However, a lack of clear delineation of their underlying pathophysiological mechanisms is a …
However, a lack of clear delineation of their underlying pathophysiological mechanisms is a …
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder
RL Dean, C Hurducas, K Hawton… - Cochrane Database …, 2021 - cochranelibrary.com
Background Many studies have recently been conducted to assess the antidepressant
efficacy of glutamate modification in mood disorders. This is an update of a review first …
efficacy of glutamate modification in mood disorders. This is an update of a review first …
[HTML][HTML] Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans
EA Miller, HT Afshar, J Mishra, RS McIntyre… - Psychiatry …, 2024 - Elsevier
Ketamine helps some patients with treatment resistant depression (TRD), but reliable
methods for predicting which patients will, or will not, respond to treatment are lacking …
methods for predicting which patients will, or will not, respond to treatment are lacking …
Recommendations for selection and adaptation of rating scales for clinical studies of rapid-acting antidepressants
C Yavorsky, E Ballard, M Opler, J Sedway… - Frontiers in …, 2023 - frontiersin.org
The novel mechanisms of action (MOA) derived from some recently introduced molecular
targets have led to regulatory approvals for rapid acting antidepressants (RAADs) that can …
targets have led to regulatory approvals for rapid acting antidepressants (RAADs) that can …
Hypersomnia as a predictor of response to intravenous ketamine/intranasal esketamine in treatment resistant depression
L Patarroyo-Rodriguez, V Pazdernik, JLV Voort… - Journal of Affective …, 2024 - Elsevier
Background Sleep disturbances are highly prevalent in depressive episodes and are linked
to higher mood severity and suicidal behaviors. Slow wave sleep (SWS) and REM sleep are …
to higher mood severity and suicidal behaviors. Slow wave sleep (SWS) and REM sleep are …
Low-dose ketamine infusion for treating subjective cognitive, somatic, and affective depression symptoms of treatment-resistant depression
Backgrounds Whether the antidepressant effects of low-dose ketamine infusion and the
therapeutic impact of Val66Met brain-derived neurotrophic factor (BDNF) polymorphism vary …
therapeutic impact of Val66Met brain-derived neurotrophic factor (BDNF) polymorphism vary …
Ketamine in COVID‐19 patients: Thinking out of the box
K Akinosoglou, A Gogos… - Journal of Medical …, 2020 - pmc.ncbi.nlm.nih.gov
Coronavirus disease 2019 (COVID‐19), identified as the disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2), was recognized as a public health …
respiratory syndrome coronavirus 2 (SARS‐CoV‐2), was recognized as a public health …
Subanaesthetic ketamine suppresses locus coeruleus mediated alertness effects-a 7T fMRI study
T Liebe, LV Danyeli, ZD Sen, M Li… - International Journal …, 2024 - academic.oup.com
Background The NMDA antagonist s-ketamine is gaining increasing use as a rapid-acting
antidepressant, although its exact mechanisms of action are still unknown. In this study, we …
antidepressant, although its exact mechanisms of action are still unknown. In this study, we …
Targeting affective mood disorders with ketamine to prevent chronic postsurgical pain
DE Willis, PA Goldstein - Frontiers in Pain Research, 2022 - frontiersin.org
The phencyclidine-derivative ketamine [2-(2-chlorophenyl)-2-(methylamino) cyclohexan-1-
one] was added to the World Health Organization's Model List of Essential Medicines in …
one] was added to the World Health Organization's Model List of Essential Medicines in …